Evidence map›Paper›PMID 33732361›Full record

ArticleOncology letters2021

Krzysztof Giannopoulos, Agnieszka Karczmarczyk, Marta Karp, Agnieszka Bojarska-Junak, Kamila Kosior, Małgorzata Kowal, Waldemar Tomczak, Marek Hus, Marcin Machnicki, Tomasz Stokłosa

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin 20-093, Poland.
Agnieszka KarczmarczykDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin 20-093, Poland.
Marta KarpDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin 20-093, Poland.
Agnieszka Bojarska-JunakDepartment of Clinical Immunology, Medical University of Lublin, Lublin 20-093, Poland.
Kamila KosiorDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin 20-093, Poland.
Małgorzata KowalDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin 20-093, Poland.
Waldemar TomczakDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin 20-093, Poland.
Marek HusDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin 20-093, Poland.
Marcin MachnickiDepartment of Immunology, Center for Biostructure Research, Medical University of Warsaw, Warsaw 02-097, Poland.
Tomasz StokłosaDepartment of Immunology, Center for Biostructure Research, Medical University of Warsaw, Warsaw 02-097, Poland.
Medical University of Lublin · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dasatinib inhibits the breakpoint cluster region-Abelson murine leukemia 1 (

Indexed as

apoptosischronic lymphocytic leukemiachronic myeloid leukemiadasatinibkinase inhibitor

Identifiers

PMID33732361
PMCPMC7905539
OpenAlexW3130652245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.